SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: NotAsBigKahuna, BooDog, sox040713, Astavakra, TheHound, Matagordaville
Search This Board: 
Last Post: 4/23/2017 5:45:57 PM - Followers: 716 - Board type: Free - Posts Today: 102

Cellceutix Corporation (CTIX)
 

http://cellceutix.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com

 
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly-traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Cellceutix's psoriasis drug candidate Prurisol completed a Phase 2 trial and Cellceutix recently launched a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at www.cellceutix.com.

Management:  http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.cellceutix.com/therapeutic-areas/

 

PIPELINE:

 

FDA DESIGNATIONS:

 

COMPLETED/UPCOMING MILESTONES:



Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines
http://www.cellceutix.com/press-release/

 
SEC Filings (CIK:0001355250):  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 
info@cellceutix.com

http://www.cellceutix.com/new-faq/


Following is a WEEKLY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CTIX News: Bahamas Development Corp. (OTC Pink: BDCI) $2.4 Million in Sales and 10% Quarterly Growth – Issues Guidance 04/17/2017 07:03:27 AM
CTIX News: Current Report Filing (8-k) 03/31/2017 04:25:24 PM
CTIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 03/29/2017 04:13:08 PM
CTIX News: Current Report Filing (8-k) 03/27/2017 11:29:27 AM
CTIX News: Current Report Filing (8-k) 02/16/2017 07:01:38 AM
PostSubject
#179315  Sticky Note April 2017: Investor & Shareholder Update BooDog 04/21/17 05:52:25 AM
#176859  Sticky Note Look --------> Cellceutix: A New Standard Of Care Matagordaville 03/30/17 09:03:52 AM
#176575  Sticky Note $CTIX Abstract out on Kevetrin ---- > Title: TheHound 03/28/17 10:12:24 AM
#175709  Sticky Note CTIX Milestones, Clinical Trials, Recent Interviews, Fact Sheets sox040713 03/18/17 06:44:12 PM
#174938  Sticky Note B-UP Due Diligence (Rev. 3/10) sox040713 03/10/17 04:08:53 PM
#179909   Yep in denial. Show me those cheap shares. septmike09 04/23/17 05:45:57 PM
#179908   Of Course He Claimed he had A Harvard degree! Giovanni 04/23/17 05:40:32 PM
#179907   Some excellent posts this weekend! Cellceutix's science just BooDog 04/23/17 05:38:58 PM
#179906   Then why are you here? septmike09 04/23/17 05:37:13 PM
#179905   Too Bad many seem to be in denial TheBunny 04/23/17 05:26:15 PM
#179904   If that's the case it just shows you tombrady12nh 04/23/17 05:23:33 PM
#179903   nobody in the world except the few on Giovanni 04/23/17 05:18:28 PM
#179902   That's the piont,he never claimed it! Should he Jhawker 04/23/17 05:17:53 PM
#179901   I don't think he did anything wrong. It septmike09 04/23/17 05:17:46 PM
#179900   Sorry but Leo opened the doors for more tombrady12nh 04/23/17 04:59:40 PM
#179899   you are entitled to interpret however you like! septmike09 04/23/17 04:50:52 PM
#179898   Looking ahead to 2017, we intend to remain septmike09 04/23/17 04:41:47 PM
#179897   More bloodshed this week, or recovery? I have snayeman 04/23/17 04:35:33 PM
#179896   I do not think so Giovanni 04/23/17 04:23:08 PM
#179894   I was replying to Justfactsmam. As far as sox040713 04/23/17 02:56:55 PM
#179892   I agree with you. My piont was that Jhawker 04/23/17 02:06:54 PM
#179891   depends on how you look at it. septmike09 04/23/17 01:36:06 PM
#179889   This post pretty much shuts down the subject. septmike09 04/23/17 01:29:28 PM
#179887   Trying reading this post by Justfactsman again: Jhawker 04/23/17 01:17:40 PM
#179886   I don't know why people sold. Tried to DesireToLearn 04/23/17 01:15:23 PM
#179885   No I think someone with a lot of septmike09 04/23/17 01:11:36 PM
#179884   Nice. Thank you JUST 10-11-12 04/23/17 01:10:12 PM
#179882   anyone here think last week's drop in share TheHound 04/23/17 12:59:48 PM
#179881   damn. imo ur comments just tore his message TheHound 04/23/17 12:36:31 PM
#179880   They would insist Menon resign lying about a Giovanni 04/23/17 12:33:04 PM
#179876   CTIX has 3 people that worked for phizer. septmike09 04/23/17 11:49:04 AM
#179875   Small biotech stocks take time as you have Jhawker 04/23/17 11:41:13 AM
#179874   It would look just like any other board Jhawker 04/23/17 11:31:58 AM
#179873   Could be the general population is using JTORENCE 04/23/17 11:22:44 AM
#179872   Would a pharmaceutical company looking to partner review Blues44 04/23/17 11:22:25 AM
#179871   You are right, but, it was more than KarinCA 04/23/17 11:04:41 AM
#179870   Made my first purchase of CTIX in 2011. That's MrW 04/23/17 10:59:02 AM
#179869   I suspect that the 3 smart investors who georgejjl 04/23/17 10:52:21 AM
#179868   No one way to know if Leo actually scottsmith 04/23/17 10:30:34 AM
#179865   Yes at the onset they were promised a Williamsc 04/23/17 10:22:53 AM
#179864   From Leo via Cabel georgejjl 04/23/17 10:22:27 AM
#179863   Does anyone with a mid to long term Giovanni 04/23/17 10:18:21 AM
#179862   https://www.google.com/search?q=CTIX&rlz=1CAACAG_enUS619US619&oq=CTIX&aqs=chrome Giovanni 04/23/17 10:13:55 AM
#179861   Brilacidin—Oral Mucositis (Phase 2 Trial) georgejjl 04/23/17 10:09:48 AM
#179860   I suspect CEO leo is getting an earful MXAMDUD 04/23/17 10:07:41 AM
#179859   Several trials are expected to end this year, no? DesireToLearn 04/23/17 10:07:21 AM
#179858   “Having already engaged in productive discussions with georgejjl 04/23/17 10:02:28 AM
#179857   Swell. TheDane 04/23/17 09:58:22 AM
#179856   Prurisol alone is still worth at least $10 georgejjl 04/23/17 09:55:33 AM
#179853   Partnerships are within a few months maybe a georgejjl 04/23/17 09:34:38 AM
#179851   If any one wants to see what Mr eventhelosers 04/23/17 09:08:55 AM
#179849   his mother Giovanni 04/23/17 08:53:21 AM
#179848   People who sign Legal documents are not responsible Giovanni 04/23/17 08:49:26 AM
#179847   * * $CTIX Video Chart 04-21-17 * * ClayTrader 04/23/17 08:44:34 AM
#179846   I would like to possibly shed some light mdphd2008 04/23/17 08:44:32 AM
PostSubject